332 related articles for article (PubMed ID: 34533850)
1. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract][Full Text] [Related]
2. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract][Full Text] [Related]
3. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
[TBL] [Abstract][Full Text] [Related]
4. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
5. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
[TBL] [Abstract][Full Text] [Related]
6. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
7. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
[TBL] [Abstract][Full Text] [Related]
8. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
[TBL] [Abstract][Full Text] [Related]
9. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
Tefferi A; Gotlib J; Pardanani A
Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
[TBL] [Abstract][Full Text] [Related]
10. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
11. Causes of hypereosinophilia in 100 consecutive patients.
Moller D; Tan J; Gauiran DTV; Medvedev N; Hudoba M; Carruthers MN; Dehghan N; van den Berghe J; Bruyère H; Chen LYC
Eur J Haematol; 2020 Sep; 105(3):292-301. PubMed ID: 32364630
[TBL] [Abstract][Full Text] [Related]
12. Primary eosinophilic disorders: a concise review.
Pardanani A; Tefferi A
Curr Hematol Malig Rep; 2008 Jan; 3(1):37-43. PubMed ID: 20425445
[TBL] [Abstract][Full Text] [Related]
13. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
14. Modern diagnosis and treatment of primary eosinophilia.
Tefferi A
Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
[TBL] [Abstract][Full Text] [Related]
15. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
Gotlib J; Cross NC; Gilliland DG
Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
[TBL] [Abstract][Full Text] [Related]
17. Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies).
Iurlo A; Cattaneo D; Gianelli U
Expert Rev Hematol; 2019 Dec; 12(12):1077-1088. PubMed ID: 31588817
[No Abstract] [Full Text] [Related]
18. Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.
Helbig G; Klion AD
Blood Rev; 2021 Sep; 49():100809. PubMed ID: 33714638
[TBL] [Abstract][Full Text] [Related]
19. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Ogbogu PU; Bochner BS; Butterfield JH; Gleich GJ; Huss-Marp J; Kahn JE; Leiferman KM; Nutman TB; Pfab F; Ring J; Rothenberg ME; Roufosse F; Sajous MH; Sheikh J; Simon D; Simon HU; Stein ML; Wardlaw A; Weller PF; Klion AD
J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
